معرفی
Dr. Nancy Sullivan is a Professor of Virology, Immunology & Microbiology at Boston University’s Chobanian & Avedisian School of Medicine and Professor of Biology in the College of Arts and Sciences. She is the Director of the National Emerging Infectious Diseases Laboratories (NEIDL), appointed in December 2022. Her research focuses on viral immunology, emerging pathogens, and pandemic preparedness, with notable contributions to Ebola vaccine development (e.g., ChAd3-Ebola) and the FDA-approved mAb114 antibody therapy (Ebanga). She has been internationally recognized for her leadership in combatting Ebola and her role in the US response to SARS-CoV-2.
Education:
- BS, Merrimack College
- MS, Harvard School of Public Health
- ScD, Harvard T.H. Chan School of Public Health
Research Interests: Dr. Sullivan’s work emphasizes vaccine development for high-consequence viruses (Ebola, Marburg, Nipah) and global health partnerships. She pioneered the 'prototype pathogen approach' to vaccine design, now a global standard. Her lab advanced Marburg/Sudan vaccines to clinical trials and discovered mAb114, saving 90% of Ebola patients when administered early. She also leads capacity-building programs in the Democratic Republic of Congo (DRC) to decentralize infectious disease research.
Scientific Awards:
- Time’s Person of the Year (2014)
- Politico’s Top 50 (2015)
- NIH Director’s Awards, NIH Staff Recognition Awards, NIAID Merit Awards
Advising & Grants: While specific student names are not listed, her work involves global collaborations and clinical trials. The NEIDL under her leadership integrates basic science, translational research, and global engagement to address emerging threats. She also directs the Sabin Vaccines Institute partnership for Marburg/Sudan vaccines.
Labs/Teams: Director of NEIDL; collaborates with the NIH’s Vaccine Research Center and the DRC on therapeutic discovery and regional research training programs.
